Efficacy of gamithromycin injection administered intramuscularly against bacterial swine respiratory disease

The aim of this study is to evaluate the safety and efficacy of gamithromycin (GAM) for the treatment of naturally occurring bacterial swine respiratory disease (SRD) administered IM. A total of 240 pigs (nine-weeks old) were selected from two sites in Heilongjiang Province of China. The pigs showed severe signs of respiratory disease. Among them, 120 pigs were randomly divided into 4 groups of low dose (3 mg/kg), middle dose (6 mg/kg), high dose (12 mg/kg) GAM IM injection and 2.5 mg/kg tulathromycin (TUL) IM injection (positive control group) for phase II clinical trial to screen effective therapeutic dose. The other 120 pigs were randomly divided into 2 groups of 6 mg/kg GAM IM injection and 2.5 mg/kg TUL IM injection (positive control group) for phase III clinical trial to further confirm the efficacy. Animals were clinically observed daily for 14 days after treatment initiation. The predominant pathogens present in pretreatment respiratory tract samples were Streptococcus suis (S. suis) and Actinobacillus pleuropneumoniae (A. pleuropneumoniae). Haemophilus parasuis (H. parasuis) and Pasteurella multocida (P. multocida) were also found in the respiratory tract. All isolates were subjected to in vitro sensitivity testing and the measured minimal inhibitory concentrations (MIC) of GAM were from 0.0625 mu g/mL to 8 mu g/mL. In all treatment groups, rectal temperature dropped and clinical index (mental status and respiratory symptom) significantly improved after treatment (P <= .05). As a result, 82.76% animals treated with the 6 mg/ kg GAM injection were cured. This was significantly higher than that of 3 mg/kg GAM injection (P <= .05) and similar to that of 12 mg/kg GAM injection and 2.5 mg/kg TUL injection (P > .05) in phase II clinical trial. In phase III clinical trial, 80.70% of animals treated with the 6 mg/kg GAM injection were cured and the cure rate was similar to that of 2.5 mg/kg TUL injection (P > .05). In conclusion, we recommended a single dose (6 mg/ kg) of GAM IM injection for the treatment of bacterial SRD.